Yonsei Med J.  2016 Mar;57(2):532-533. 10.3349/ymj.2016.57.2.532.

A Case of Dasatinib-Induced Nephrotic Syndrome in a Child with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

• Lim YT
• Kim YJ
• Park YH
• Hah JO
• Lee JM

• KMID: 2374065
• DOI: http://doi.org/10.3349/ymj.2016.57.2.532

Abstract

No abstract available.

Figure

• 

  Fig. 1 (A) Glomerulus had no cellular proliferation or capillary wall thickening, and surrounding tubules are also unremarkable on PAS staining (×200). (B) Electron microscopically, most foot processes were fused. Electron dense deposits are not present (×3000).

Reference

1. Skolnik JM, Adamson PC. Tyrosine kinase inhibitors in pediatric malignancies. Cancer Invest. 2007; 25:606–612.

2. Hunger SP. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia. Hematology Am Soc Hematol Educ Program. 2011; 2011:361–365.

3. Ruebner RL, Copelovitch L, Evageliou NF, Denburg MR, Belasco JB, Kaplan BS. Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature. Pediatr Nephrol. 2014; 29:863–869.

4. Aricò M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000; 342:998–1006.

5. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009; 27:5175–5181.

6. Porkka K, Koskenvesa P, Lundán T, Rimpiläinen J, Mustjoki S, Smykla R, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008; 112:1005–1012.

7. Wallace E, Lyndon W, Chumley P, Jaimes EA, Fatima H. Dasatinibinduced nephrotic-range proteinuria. Am J Kidney Dis. 2013; 61:1026–1031.

8. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003; 111:707–716.